FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
March 02, 2020 16:01 ET
|
FibroGen, Inc
Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic...
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
December 02, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s...
FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019
November 04, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November...
CORRECTION - FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019
August 01, 2019 20:39 ET
|
FibroGen, Inc
SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by FibroGen, Inc (NASDAQ: FGEN) we are advised by the company the “Live (U.S./Canada)”...
FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019
August 01, 2019 19:24 ET
|
FibroGen, Inc
SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that it will report second quarter 2019 financial results on Thursday, August 8, 2019 after market...
FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018
November 02, 2018 17:02 ET
|
FibroGen, Inc
Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT) SAN FRANCISCO, Nov. 02, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today...
FibroGen Reports Second Quarter 2018 Financial Results
August 07, 2018 16:02 ET
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
August 01, 2018 17:21 ET
|
FibroGen, Inc
SAN FRANCISCO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that it will report second quarter 2018 financial results on Tuesday,...
FibroGen Reports Third Quarter 2017 Financial Results
November 08, 2017 16:02 ET
|
FibroGen, Inc
Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results ReportedConference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time ...
FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017
October 30, 2017 20:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report financial results for the third quarter...